Lipocine Inc. Announces 2024 Annual Meeting of Stockholders on June 5
Ticker: LPCN · Form: DEF 14A · Filed: Apr 23, 2024 · CIK: 1535955
| Field | Detail |
|---|---|
| Company | Lipocine Inc. (LPCN) |
| Form Type | DEF 14A |
| Filed Date | Apr 23, 2024 |
| Risk Level | low |
| Pages | 16 |
| Reading Time | 20 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: Lipocine Inc., Annual Meeting, Proxy Statement, Stockholder Vote, Corporate Governance
TL;DR
<b>Lipocine Inc. invites stockholders to its 2024 Annual Meeting on June 5, 2024, urging them to vote via the Internet or proxy card.</b>
AI Summary
Lipocine Inc. (LPCN) filed a Proxy Statement (DEF 14A) with the SEC on April 23, 2024. Lipocine Inc. will hold its 2024 Annual Meeting of Stockholders on June 5, 2024, at 10:00 a.m. Mountain Daylight Time. The meeting will take place at Lipocine's offices located at 675 Arapeen Drive, Suite 202, Salt Lake City, Utah 84108. Stockholders are urged to vote via the Internet or by returning a completed proxy card. The company emphasizes the importance of voting due to rules that may prevent brokers from voting uninstructed shares on non-routine matters. The Proxy Statement and notice of the meeting are attached to this filing.
Why It Matters
For investors and stakeholders tracking Lipocine Inc., this filing contains several important signals. The annual meeting is a critical forum for stockholders to exercise their voting rights on corporate matters, including director elections and other proposals. The 'notice and access' approach for proxy materials aims to reduce printing and mailing costs while ensuring stockholders have access to important information for their vote.
Risk Assessment
Risk Level: low — Lipocine Inc. shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting, containing no new material financial or operational information that would indicate significant risk.
Analyst Insight
Stockholders should review the proxy statement and vote their shares to ensure their voice is heard on corporate governance matters.
Key Numbers
- 2024 — Annual Meeting Year (Year of the Annual Meeting of Stockholders.)
- June 5 — Meeting Date (Date of the Annual Meeting of Stockholders.)
- 10:00 a.m. Mountain Daylight Time — Meeting Time (Time of the Annual Meeting of Stockholders.)
Key Players & Entities
- Lipocine Inc. (company) — Registrant name and company holding the annual meeting.
- Mahesh V. Patel, Ph.D. (person) — President and Chief Executive Officer of Lipocine Inc.
- June 5, 2024 (date) — Date of the Annual Meeting of Stockholders.
- 675 Arapeen Drive, Suite 202, Salt Lake City, Utah 84108 (location) — Address of Lipocine's offices where the meeting will be held.
FAQ
When did Lipocine Inc. file this DEF 14A?
Lipocine Inc. filed this Proxy Statement (DEF 14A) with the SEC on April 23, 2024.
What is a DEF 14A filing?
A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by Lipocine Inc. (LPCN).
Where can I read the original DEF 14A filing from Lipocine Inc.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Lipocine Inc..
What are the key takeaways from Lipocine Inc.'s DEF 14A?
Lipocine Inc. filed this DEF 14A on April 23, 2024. Key takeaways: Lipocine Inc. will hold its 2024 Annual Meeting of Stockholders on June 5, 2024, at 10:00 a.m. Mountain Daylight Time.. The meeting will take place at Lipocine's offices located at 675 Arapeen Drive, Suite 202, Salt Lake City, Utah 84108.. Stockholders are urged to vote via the Internet or by returning a completed proxy card..
Is Lipocine Inc. a risky investment based on this filing?
Based on this DEF 14A, Lipocine Inc. presents a relatively low-risk profile. The filing is a routine proxy statement for an annual meeting, containing no new material financial or operational information that would indicate significant risk.
What should investors do after reading Lipocine Inc.'s DEF 14A?
Stockholders should review the proxy statement and vote their shares to ensure their voice is heard on corporate governance matters. The overall sentiment from this filing is neutral.
How does Lipocine Inc. compare to its industry peers?
Lipocine Inc. operates in the pharmaceutical preparations industry, focusing on developing drug candidates.
Are there regulatory concerns for Lipocine Inc.?
The filing is a standard DEF 14A (Definitive Proxy Statement) under the Securities Exchange Act of 1934, Rule 14a-101, related to annual shareholder meetings.
Industry Context
Lipocine Inc. operates in the pharmaceutical preparations industry, focusing on developing drug candidates.
Regulatory Implications
The filing is a standard DEF 14A (Definitive Proxy Statement) under the Securities Exchange Act of 1934, Rule 14a-101, related to annual shareholder meetings.
What Investors Should Do
- Review the full Proxy Statement for details on proposals and director nominees.
- Vote your shares either online or by returning the proxy card.
- Attend the Annual Meeting on June 5, 2024, if possible, to vote in person.
Key Dates
- 2024-06-05: Annual Meeting of Stockholders — Key date for stockholders to vote on company matters.
- 2024-04-23: Filing Date — Date the Definitive Proxy Statement was filed with the SEC.
Year-Over-Year Comparison
This filing is a routine proxy statement for the annual meeting and does not represent a change from previous filings in terms of new financial or operational disclosures.
Filing Stats: 4,896 words · 20 min read · ~16 pages · Grade level 11.2 · Accepted 2024-04-23 16:05:19
Filing Documents
- formdef14a.htm (DEF 14A) — 721KB
- formdef14a_001.jpg (GRAPHIC) — 15KB
- formdef14a_003.jpg (GRAPHIC) — 65KB
- formdef14a_004.jpg (GRAPHIC) — 53KB
- proxy_001.jpg (GRAPHIC) — 248KB
- proxy_002.jpg (GRAPHIC) — 180KB
- 0001493152-24-015694.txt ( ) — 1495KB
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS, DIRECTORS AND MANAGMENT
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS, DIRECTORS AND MANAGMENT 19
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION 20 PROPOSAL NO. 5 - AMENDMENT AND RESTATEMENT OF THE FOURTH AMENDED AND RESTATED 2014 STOCK AND INCENTIVE PLAN 27 OTHER MATTERS 35 APPENDIX I 37 ANNUAL MEETING OF STOCKHOLDERS We have sent you this Proxy Statement and the enclosed proxy card because the Board is soliciting your proxy to vote at our 2024 Annual Meeting of Stockholders to be held on Wednesday, June 5, 2024 at our offices at 675 Arapeen Drive, Suite 202, Salt Lake City, Utah 84108, at 10:00 a.m., Mountain Daylight Time, and at any adjournments or postponements thereof. This Proxy Statement summarizes information about the proposals to be considered at the Annual Meeting and other information you may find useful in determining how to vote. The proxy card is the means by which you actually authorize another person to vote your shares in accordance with your instructions. This year, we are providing access to this year’s proxy materials primarily over the Internet under the Securities and Exchange Commission’s “Notice and Access” rules. The Notice of Internet Availability of Proxy Materials (the “Notice”) is first being mailed on or about April 23, 2024 to each of our stockholders entitled to notice of and to vote at the Annual Meeting. This Notice will contain instructions on how to access this Proxy Statement, our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “Annual Report”) and how to vote via the Internet and e-mail. The Notice will also include instructions on how you can receive a paper copy of your proxy materials. The Proxy Statement and the Annual Report both are available online at: www.proxyvote.com . Web links and addresses contained in this Proxy Statement are provided for convenience only, and the content on the referenced websites does not constitute a part of this Proxy Statement. Information About the Annual Meeting Why am I receiving these materials? The purpose